Loading clinical trials...
Loading clinical trials...
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D and Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (HR-MDS)
Conditions
Interventions
GSK3745417
Locations
10
Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Dresden, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Meldola FC, Italy
GSK Investigational Site
Perugia, Italy
GSK Investigational Site
Roma, Italy
Start Date
September 20, 2022
Primary Completion Date
March 4, 2024
Completion Date
March 4, 2024
Last Updated
March 25, 2025
NCT07216443
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions